Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Lifeway Foods Inc. ( LWAY - Snapshot Report ) , which manufactures dairy and non-dairy health food products, posted earnings of 9 cents per share in the third quarter of 2012. The result fell short of the Zacks Consensus Estimate by a penny, but comfortably beats the year-ago quarter earnings of 6 cents per share.
Gross sales in the quarter rose 16.0% year over year to $22.5 million, driven by higher sales and increased customer acceptance for its flagship product ‘Kefir’ as well as other product lines including Bio Kefir and ProBugs organic Kefir for kids. Net sales also jumped 16.0% to $20.6 million.
During the quarter, gross profit enhanced 18% to $7.5 million and gross margin was flat at 33%, attributed to a 20% dip in conventional costs, the largest ingredient for the company, partially offset by a 10% hike in the price of milk.
Operating expense nudged up 13% year over year to $5.4 million, primarily due to higher general and administrative expenses particularly related to increased investments in marketing and advertising for brand awareness as well as increased selling and amortization expenses. However, operating income surged 31.3% to $2.1 million, aided by an increase in gross margin.
Liquidity Position
As of September 30, 2012, Lifeway Foods had cash and cash equivalents of $2.4 million versus $0.86 million at September 30, 2011. Shareholders’ equity were $38.4 million versus $35.8 million in the year ago quarter.
Our Take
Lifeway continues to focus on distributing its flagship product “Kefir” along with the growth of business. Further, the company is also making efforts to keep enhancing shareholder’s value. However, the price of milk is likely to be a headwind through the rest of 2012.
We currently retain a Zacks #3 Rank on the stock, which translates into a short-term ‘Hold’ rating. We are also maintaining our long-term ‘Neutral’ recommendation.
However, one of its peers Feihe International, Inc. ( ADY - Snapshot Report ) currently has a Zacks #1 Rank, implying a ‘Strong Buy’ rating over the short term.
Read the full Snapshot Report on ADY
Read the full Snapshot Report on LWAY